24 results on '"Strohmaier, Christine"'
Search Results
2. Brain-Derived Neurotrophic Factor and the Developing Chick Retina
3. List of Contributors
4. BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension
5. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
6. P1-298: Tolerability, safety, and efficacy of the 1-step titration scheme of rivastigmine patch 10 cm2 in japanese patients with mild-to-moderate Alzheimer's disease: A 24-week randomized controlled study
7. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
8. P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY
9. Long-term Safety of Rivastigmine in Parkinson Disease Dementia
10. Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease
11. P3-275: Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study
12. P3-278: The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA)
13. P3-423: Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time-to-m
14. P3-424: High-dose 13.3 mg/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis
15. P3-422: Comparisons of patient characteristics in subpopulations of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study
16. Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimers Disease
17. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease.
18. The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study
19. Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study
20. Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time-to-meet decline
21. Comparisons of patient characteristics in subpopulations of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study
22. High-dose 13.3 mg/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis
23. Tolerability, safety, and efficacy of the 1-step titration scheme of rivastigmine patch 10 cm2 in japanese patients with mild-to-moderate Alzheimer’s disease: A 24-week randomized controlled study.
24. Up-titration to high-dose 13.3 mg/24 h Rivastigmine transdermal patch may provide greater benefit to Alzheimer's disease patients compared to concomitant use of 9.5 mg/24 h patch and memantine: Results from the optima study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.